PYC Therapeutics Ltd
ASX:PYC
PYC Therapeutics Ltd
PYC Therapeutics Ltd. is a drug-development company, which offers a new generation of RNA therapeutics to meet unmet need in disease. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. The firm has RNA targeted therapeutics design capabilities to deliver technology based on cell penetrating peptides (CPPs). The firm develops a pipeline of therapies, including three preclinical stage programs, which are focused on inherited eye diseases and preclinical discovery efforts, which are focused on neurodegenerative diseases. The Company’s lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate VP-002, which is focused on treating autosomal dominant optic atrophy (ADOA) and PYC-001 drug candidate to treat diabetic retinopathy. Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The firm's discovery and laboratory operations are located in Australia.
PYC Therapeutics Ltd. is a drug-development company, which offers a new generation of RNA therapeutics to meet unmet need in disease. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. The firm has RNA targeted therapeutics design capabilities to deliver technology based on cell penetrating peptides (CPPs). The firm develops a pipeline of therapies, including three preclinical stage programs, which are focused on inherited eye diseases and preclinical discovery efforts, which are focused on neurodegenerative diseases. The Company’s lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate VP-002, which is focused on treating autosomal dominant optic atrophy (ADOA) and PYC-001 drug candidate to treat diabetic retinopathy. Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The firm's discovery and laboratory operations are located in Australia.
Strong Pipeline Progress: PYC remains on track to bring three first-in-class, potentially disease-modifying drugs into human studies by year-end, with an 18-month focus on demonstrating human safety and early efficacy.
RP11 Clinical Milestone: The company reported its first encouraging human efficacy data for RP11, with a patient showing improved visual function and microperimetry readings after treatment.
Refined Trial Approach: PYC is now enrolling earlier-stage RP11 patients to maximize the chance of detecting efficacy signals quickly, without limiting the drug’s ultimate patient population.
ADOA and Pipeline Expansion: Regulatory submission for the ADOA program is imminent, with first human dosing targeted for Q3 2024. Safety data from RP11 supports the approach.
Kidney Program Advances: The polycystic kidney disease candidate showed strong preclinical safety and high kidney tissue drug concentration, with first-in-human studies expected after GLP tox studies.
Commercial Strategy Options: Management highlighted both traditional capital raising and potential out-licensing deals, as earlier-stage biotech assets are attracting interest in $1–2B transactions.
Upcoming Data Catalysts: Multiple clinical readouts are expected across the portfolio throughout 2024, especially in the RP11 and ADOA programs.
